A real-time characterization method to rapidly optimize molecular beacon signal for sensitive nucleic acids analysis
- 363 Downloads
This research demonstrates an integrated microfluidic titration assay to characterize the cation concentrations in working buffer to rapidly optimize the signal-to-noise ratio (SNR) of molecular beacons (MBs). The “Microfluidic Droplet Array Titration Assay" (MiDATA) integrated the functions of sample dilution, sample loading, sample mixing, fluorescence analysis, and re-confirmation functions all together in a one-step process. It allows experimentalists to arbitrarily change sample concentration and acquire SNR measurements instantaneously. MiDATA greatly reduces sample dilution time, number of samples needed, sample consumption, and the total titration time. The maximum SNR of molecular beacons is achieved by optimizing the concentrations of the monovalent and divalent cation (i.e., Mg2+ and K+) of the working buffer. MiDATA platform is able to reduce the total consumed reagents to less than 50 μL, and decrease the assay time to less than 30 min. The SNR of the designated MB is increased from 20 to 126 (i.e., enhanced the signal 630 %) using the optimal concentration of MgCl2 and KCl determined by MiDATA. This novel microfluidics-based titration method is not only useful for SNR optimization of molecular beacons but it also can be a general method for a wide range of fluorescence resonance energy transfer (FRET)-based molecular probes.
KeywordsMolecular beacons FRET Titration Lab-on-a-chip Microfluidics
- 7.Tung CH, Mahmood U, Bredow S, Weissleder R (2000) In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res 60(17):4953–4958Google Scholar
- 16.Stryer L, Haugland RP (1967) Energy transfer—a spectroscopic ruler. Proc Natl Acad Sci USA 58(2):719–726Google Scholar
- 39.Muradoglu M, Stone HA (2005) Mixing in a drop moving through a serpentine channel: a computational study. Phys Fluids 17(7):073305–073309Google Scholar
- 41.Shattuckeidens D, Mcclure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M, Brody L, Friedman L, Ostermeyer E, Szabo C, King MC, Jhanwar S, Offit K, Norton L, Gilewski T, Lubin M, Osborne M, Black D, Boyd M, Steel M, Ingles S, Haile R, Lindblom A, Olsson H, Borg A, Bishop DT, Solomon E, Radice P, Spatti G, Gayther S, Ponder B, Warren W, Stratton M, Liu QY, Fujimura F, Lewis C, Skolnick MH, Goldgar DE (1995) A collaborative survey of 80 mutations in the Brca1 breast cancer and ovarian cancer susceptibility gene— implications for presymptomatic testing and screening. JAMA 273(7):535–541CrossRefGoogle Scholar